Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anik Patel

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Blood Advances|January 30, 2025
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucelFrederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
American Journal of Hematology|March 20, 2024
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapyMatthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Blood Advances|January 30, 2025
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucelFrederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
American Journal of Hematology|March 20, 2024
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapyMatthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, et al.
Pageof 3